Ultragenyx Pharmaceutical Inc. (RARE) Q3 2024 Earnings Call Transcript

By Sa Transcripts

Ultragenyx Pharmaceutical Inc. (RARE) Q3 2024 Earnings Call Transcript

Chris Raymond - Piper Sandler

Tazeen Ahmad - Bank of America

Malcolm Kuno - JPMorgan

Gena Wang - Barclays

Lydia Erdman - Goldman Sachs

Maury Raycroft - Jefferies

Mehdi Goudarzi - Truist Securities

Yaron Werber - TD Cowen

Yigal Nochomovitz - Citi

Thomas Yip - H.C. Wainwright

Jack Allen - Baird

Joe Schwartz - Leerink Partners

Michael Riad - Morgan Stanley

Kristen Kluska - Cantor Fitzgerald

Dae Gon Ha - Stifel

Good afternoon and welcome to the Ultragenyx Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. At the end of the prepared remarks, you will have opportunity to ask questions during the question-and-answer portion of the call.

It is now my pleasure to turn the call to Joshua Higa, Vice President of Investor Relations.

Joshua Higa

Thank you. We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Erik Harris, Chief Commercial Officer; Howard Horn, Chief Financial Officer; and Eric Crombez, Chief Medical Officer.

I'd like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings.

Thanks Josh and good afternoon everyone. This is a great time for Ultragenyx as we successfully completed development work

Previous articleNext article

POPULAR CATEGORY

industry

6758

fun

8617

health

6738

sports

8880